CMS Open Payments · Program Year 2024
NuSmile, Ltd.
NuSmile, Ltd. reported $310,225.95 across General Payments, Research, and Ownership to 735 physicians and teaching hospitals across 735 transactions.
- $310.2K Above-median payer
- All-tracks total
- 735 Above-median volume
- Transactions
- 735 Above-median reach
- Recipients
- +$41.1K
- General Payments vs PY2023
NuSmile, Ltd. reported $310,225.95 across all CMS Open Payments tracks (General + Research + Ownership) to 735 physicians and teaching hospitals in Program Year 2024 - ranking #887 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $310,225.95, averaging $422.08 per recipient.
NuSmile, Ltd.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
36/100
Total payments
F
13/100
Transaction volume
F
15/100
Physician reach
F
16/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer nusmile-ltd NuSmile, Ltd.
$310.2K · #887/1,925 · 0.0% industry · PY2024
- TOT $310.2K
- RANK #887
- SHARE 0.0%
- TXN 735
- RCP 735
- CAT 8
- GEN $310.2K
- ΔGEN +$41.1K
- TOP1 29.2%
- PY 2024
Volume peers
Nearest volume peer: Luminex Corporation ($309.0K)
NuSmile, Ltd. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
NuSmile, Ltd.'s CMS-reported General Payments increased by $41.1K (+15.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NUSMILE, LTD.PY2023: NUSMILE, LTD.PY2024: NuSmile, Ltd.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $269,128.98
- PY2024
- $310,225.95
What the Data Shows for NuSmile, Ltd.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For NuSmile, Ltd. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Honoraria" leads the 8-category general-payment breakdown below at $107.4K (34.6% of General Payments, 46 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 8 types of general payments, NuSmile, Ltd.'s largest category was "Honoraria" at $107.4K - 34.6% of General Payments.
NuSmile, Ltd. reports 8 general-payment categories - the top three are Honoraria (34.6%), Travel and Lodging (22.7%), and Consulting Fee (17.5%). The remaining 5 categories make up 25.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: NuSmile, Ltd. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How NuSmile, Ltd. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $107.4K | 46 | 34.6% |
| Travel and Lodging | $70.5K | 96 | 22.7% |
| Consulting Fee | $54.4K | 25 | 17.5% |
| Compensation for Faculty or Speaker (Medical Education) | $37.3K | 33 | 12.0% |
| Food and Beverage | $16.6K | 471 | 5.4% |
| Entertainment | $15.3K | 35 | 4.9% |
| Education | $8.4K | 16 | 2.7% |
| Gift | $463.98 | 13 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $210,218.29 (67.8%) of $310,225.95 in this company's General Payments records across 347 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for NuSmile, Ltd.
The five named recipients with the highest reported General Payments from this company
- 1
Euphemia Johnson
$90,578.88 across 84 reported transactions
- 2
William Waggoner
$55,564.97 across 30 reported transactions
- 3
Matthew Lucero
$23,710.95 across 35 reported transactions
- 4
Ryan Walsh
$20,487.61 across 17 reported transactions
- 5
Patrick Ruck
$19,875.88 across 24 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
NuSmile, Ltd.'s spend rank (#887 of 1,925, top 46% by spend) and concentration rank (#903 of 1,838, top 49% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Carestream Dental, LLC : $175.9K total payments, HHI 1402
- Daxor Corporation : $270.6K total payments, HHI 1400
- US Retina LLC : $355.0K total payments, HHI 1391
- Biogen, Inc. : $9.2M total payments, HHI 1387
- Helsinn Therapeutics (U.S.), Inc. : $24.3K total payments, HHI 1382
- Fusion Orthopedics, LLC. : $5.0K total payments, HHI 1377
- NuSmile, Ltd. (this company) : $310.2K total payments, HHI 1377
- Orpyx Medical Technologies US Inc. : $205.97 total payments, HHI 1372
- Otsuka Pharmaceutical Co., Ltd. : $357.1K total payments, HHI 1372
- GLW, Inc : $30.6K total payments, HHI 1348
- DePuy Synthes Products, Inc. : $101.4M total payments, HHI 1338
- Piramal Critical Care : $111.8K total payments, HHI 1328
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as NuSmile, Ltd.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about NuSmile, Ltd..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with NuSmile, Ltd..
Showing 6 of 1,924 companies with CMS-reported payment data.
LeMaitre Vascular, Inc.
Medyssey USA, Inc
kaleo, Inc.
Cryo Specialty Medical, LLC
Ottobock SE & Co. KGaA
Put this to use
NuSmile, Ltd. ranks #887 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just NuSmile, Ltd.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.